Erbitux ®
An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001. Imclone has a license to the synergism patent. Erbitux Sales in 2007 exceeded 1B$ (Yeda).
1588839847.png)